Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.

Publikation

Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.

Wissenschaftlicher Artikel/Review - 23.12.2022

Amstad Andrea, Papagiannoulis Eleftherios, Scherer Almut, Rubbert-Roth Andrea, Finckh Axel, Mueller Ruediger, Dudler Jean, Möller Burkhard, Villiger Peter M, Schulz Martin, Kyburz Diego

Zitation

Amstad A, Papagiannoulis E, Scherer A, Rubbert-Roth A, Finckh A, Mueller R, Dudler J, Möller B, Villiger P, Schulz M, Kyburz D. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy. Rheumatology (Oxford) 2022; 62:89-97.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Rheumatology (Oxford) 2022; 62

Veröffentlichungsdatum

23.12.2022

eISSN (Online)

1462-0332

Seiten

89-97

Kurzbeschreibung/Zielsetzung

JAK Inhibitors (JAKi) are recommended DMARDs for patients with moderate-to-severe RA who failed first-line therapy with methotrexate. There is a lack of data allowing an evidence-based choice of subsequent DMARD therapy for patients who had discontinued JAKi treatment. We aimed to compare the effectiveness of TNF inhibitor (TNFi) therapy vs JAKi vs other mode of action (OMA) biologic DMARD (bDMARD) in RA patients who were previously treated with a JAKi.